Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Revenue of Vaxcyte, Inc. (PCVX)
Revenue in 2023 (TTM): $
According to Vaxcyte, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Vaxcyte, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-75,000,000 | $-464,885,000 | $-402,266,000 | $-402,266,000 |
| 2022 | $ | $-9,196,000 | $-214,289,000 | $-223,485,000 | $-239,640,000 |
| 2021 | $ | $-1,800,000 | $-98,277,000 | $-100,077,000 | $-100,084,000 |
| 2020 | $ | $-1,405,000 | $-87,805,000 | $-89,217,000 | $-87,819,000 |
| 2019 | $ | $-1,232,000 | $-49,002,000 | $-50,274,000 | $-53,499,000 |
| 2018 | $ | $-1,036,999 | $-28,373,000 | $-29,485,000 | $-29,485,000 |
| 2017 | $ | $ | $-17,208,000 | $-17,238,000 | $-17,238,000 |